Johnson & Johnson's Johnson & Johnson
Johnson & Johnson, the foremost and most extensive innovation leader in the US healthcare sector, declared on Friday its plan to invest over $55 billion in manufacturing, research and development, and technology within the United States over the next four years.
As stated by Johnson and Johnson, this investment marks a 25 percent increase compared to the previous four years and builds on the company’s already significant investment levels in the US, which were influenced by the enactment of the 2017 Tax Cuts & Jobs Act.
“Today’s announcements enhance our nearly 140-year legacy as a driving force of American innovation addressing the most pressing healthcare challenges globally,” remarked Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson. “Our heightened investment in the US commences with the groundbreaking of a state-of-the-art facility in North Carolina, which will not only create jobs domestically but also produce advanced medicines for patients in the United States and around the globe.”
In addition to the facility located in Wilson, North Carolina, the Company plans to significantly increase its investment in the United States over the next four years. This expansion will encompass the establishment of three new advanced manufacturing facilities and the enhancement of several existing locations within the Company’s Innovative Medicine and medtech sectors, resulting in the creation of high-paying, high-technology jobs. The Company will provide additional details about these sites as they become available.
Moreover, the investment strategy includes substantial funding for a comprehensive research and development infrastructure focused on creating lifesaving and transformative treatments in fields such as oncology, neuroscience, immunology, cardiovascular diseases, and robotic surgery. Enhanced technology investments will facilitate faster drug discovery and development, support workforce training initiatives, and improve overall business operations.
The company’s announcement reveals that the investment in North Carolina will generate employment opportunities starting today in Wilson, where the Company is officially commencing construction of its new, 500,000-square-foot, cutting-edge biologics manufacturing facility.
The statement emphasized the goal to “enhance our capacity to produce next-generation treatments for individuals affected by cancer, as well as immune-mediated and neurological disorders, both in the United States and globally. This initiative is expected to support around 5,000 jobs during the construction phase and create over 500 permanent positions in North Carolina.”
Johnson & Johnson operates more manufacturing sites in the United States than in any other nation and is a prominent contributor to American innovation and research and development. With a focus on pharmaceuticals and medical technology, the Company uniquely possesses the capability to address a wide range of diseases.
From cardiology and oncology to mental health and vision care, as well as cell therapies and robotics, the extensive expertise and resources of Johnson & Johnson are unparalleled.
